Separately today, Lion said it will integrate Xennex's human genes compendium GeneCards with its SRS technology.
According to Lion, the Biobase consolidation will enable SRS users to access Biobase's network and cellular pathway information. The
By associating the Biobase content with biological data offered through SRS, "scientists will be able to view networks and cellular pathways in a larger biomedical context," Lion said.
In the Xennex deal, Lion said that integrating SRS and GeneCards could help pharma companies improve drug research and development. Lion CEO Thure Etzold said in a statement that this deal represents "the first step" of the firms' collaboration.
Financial terms for either deal were not disclosed.